Samsung Biologics (207940.KS) Earnings Analysis
Samsung Biologics (207940.KS) next reports earnings on 2026-07-23, consensus EPS 8,971.82 KRW. Last quarter (2026-04-22) it beat with EPS 9,924.66 KRW vs 9,544.89 KRW est (+4%). It has beaten estimates in 4/6 recent quarters (67%). Trailing P/E 33.97.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 207940.KS next report earnings?
| Next earnings date | 2026-07-23 |
|---|---|
| Consensus EPS estimate | 8,971.82 KRW |
| Revenue estimate | 1311.60B |
207940.KS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-22 | 9,924.66 KRW | 9,544.89 KRW | +4% | Beat |
| 2026-01-21 | 10,935.49 KRW | 11,295.21 KRW | -3.2% | Miss |
| 2025-07-22 | 4,618.91 KRW | 4,660.28 KRW | -0.9% | Miss |
| 2025-01-22 | 4,340.97 KRW | 3,741.23 KRW | +16% | Beat |
| 2024-10-23 | 3,716 KRW | 3,434.36 KRW | +8.2% | Beat |
| 2024-07-24 | 4,468 KRW | 3,405.23 KRW | +31.2% | Beat |
Beat rate: 4/6 (67%) over reported quarters with consensus data.
207940.KS valuation and analyst view
| Trailing P/E | 33.97 |
|---|---|
| Trailing EPS | 40,615.14 KRW |
| Price / book | 8.05 |
| Dividend yield | 0.00% |
| Market cap | 63511.18B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Samsung Biologics (207940.KS)'s next earnings date?
Samsung Biologics is next scheduled to report on 2026-07-23, with a consensus EPS estimate of 8971.82 KRW and revenue estimate of 1311.60B.
Did 207940.KS beat earnings last quarter?
In its 2026-04-22 report, 207940.KS posted EPS of 9924.66 KRW versus a 9544.89 KRW estimate — a beat of 4%.
What is 207940.KS's earnings track record?
Over the last 6 reported quarters with consensus data, 207940.KS beat estimates 4 times (67%).
What is 207940.KS's current P/E ratio and EPS?
207940.KS trades at a trailing P/E of 33.97 on trailing EPS of 40615.137002595155 KRW.
What do analysts rate 207940.KS?
207940.KS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.